SeaStar Medical Q3 net loss narrows

SeaStar Medical Holding

13/11/2025 21:26

Overview

SeaStar Medical Q3 net loss narrows to $3.5 mln from $4.5 mln year-over-year

Company raised $12.4 mln to strengthen balance sheet and fund future operations

SeaStar Medical expands QUELIMMUNE therapy to three new top-rated children's hospitals

Outlook

Company raised $12.4 mln to support future operations

SeaStar Medical sees strong QUELIMMUNE sales in early Q4

Result Drivers

Research and development expenses for the three months ended September 30, 2025, and 2024, were $1.9 million and $2.3 million, respectively

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.13
Q3 Net Income
-$3.47 mln
Q3 Operating Expenses
$3.75 mln
Q3 Operating Income
-$3.58 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $2.00, about 75% above its November 12 closing price of $0.50

Press Release: ID:nGNX993tTW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)